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rom Knowledge to Practice in Chronic
ardiovascular Disease: A Long and Winding Road
umit R. Majumdar, MD, MPH,* Finlay A. McAlister, MD, MSC,* Curt D. Furberg, MD, PHD†
dmonton, Alberta, Canada; and Winston-Salem, North Carolina
Although clinical practices evolve over time, the translation of specific research evidence into
clinical practice is unpredictable, inconsistent, and complex. In this paper, we use examples
from chronic cardiovascular conditions to: 1) highlight two types of care gaps; 2) describe the
most common potential barriers to the application of evidence into clinical care; and 3)
outline which of the strategies for translating evidence into clinical care have been shown to
be ineffective, which strategies have been shown to be effective and to describe some untested
approaches that hold promise. (J Am Coll Cardiol 2004;43:1738–42) © 2004 by the
American College of Cardiology Foundatione
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ilthough clinical practice does evolve over time, changes in
esponse to published evidence are unpredictable in timing
nd magnitude, highly variable between geographic areas
nd individual clinicians, and may even be inconsistent with
he evidence (1,2). Indeed, the mere publication of a study
s rarely enough to change clinical practice. In this perspec-
ive article, we will illustrate the concept of “care gaps” in
ardiovascular disease, explore barriers to best practice in the
ommunity setting, and examine potential solutions to
nhance the transfer of research evidence to clinical practice.
he evidence base that defines care gaps in hospitalized
atients and defines the means by which the quality of care
or acute medical conditions may be improved is relatively
obust (3–5). Because care gaps for chronic cardiovascular
onditions dealt with in the outpatient setting are larger
han for those acute conditions dealt with in hospitals (2)
nd because less is known about them (3), we chose to focus
n them in this article.
HAT IS A CARE GAP?
care gap refers to a discrepancy between processes of care
hat have been defined as best practice on the basis of
igh-quality evidence (for therapeutics, we define this as
ne or more randomized clinical trials [RCTs]) and the care
rovided in usual clinical practice. Care gaps are often
escribed for medications or surgical interventions, but they
ay also include suboptimal application of tests (e.g.,
chocardiography in heart-failure [HF] patients, coronary
ngiography in patients with angina) necessary for either
iagnosing or tailoring treatment.
Care gaps include those situations in which proven
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M003, accepted December 23, 2003.fficacious interventions (i.e., those in which the benefits
utweighed the harms in RCTs) are under-used or under-
osed. For example, only 34% to 60% of eligible outpatients
n Europe, Canada, and the U.S. receive angiotensin-
onverting enzyme (ACE) inhibitors and beta-blockers for
F, aspirin and beta-blockers for coronary artery disease, or
arfarin for atrial fibrillation (2,6,7). Although less com-
on, care gaps also include those situations in which
herapies without proven benefit on hard outcomes such as
eath or hospitalization, or in some cases even potential
arm (i.e., those in which the harms outweighed the
enefits when evaluated in RCTs), are used. This type of
are gap may arise when a therapy comes into vogue on the
asis of its effects on surrogate outcomes before the defin-
tive RCT(s) with hard outcomes has been completed (the
idespread use of class I antiarrhythmic agents in patients
ith ventricular ectopy before the Cardiac Arrhythmia
uppression [CAST] trial proved they were harmful is the
ost widely cited example of this type of care gap) (8,9).
Although they are universally present, the magnitude of
are gaps varies within and across individual practices. For
xample, the use of ACE inhibitors or beta-blockers in HF
aries across geographic areas, between specialists and non-
pecialists, and between patient subgroups defined by age,
ender, and co-existing illnesses (6,7,10).
HAT ARE THE BARRIERS
HAT CREATE CARE GAPS?
t the outset, it should be acknowledged that even in
ardiology the literature is incomplete and there are many
ray areas with insufficient evidence to define “best prac-
ice.” However, in those situations where RCT evidence
oes exist, the barriers to the application of this evidence in
atient care can be grouped into four categories (Table 1)
11).
First, the evidence itself may be unconvincing, even when
t passes the quality filters endorsed by the Evidence-Basededicine Working Group (12). This is particularly so when
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May 19, 2004:1738–42 Knowledge Translation in Cardiologyhe RCT evidence is of uncertain clinical significance due to
mall sample sizes, short or incomplete follow-up, compar-
sons with inappropriate control groups, reporting of surro-
ate outcomes rather than clinical end points, or findings
hat are statistically significant but of questionable clinical
elevance (13). Moreover, the evidence may be of question-
ble import when limited to one intervention while patients
ith that condition are usually treated with multiple ther-
pies concurrently (13) or when multiple trials yield differ-
nt results (14). Further, most RCTs are conducted in
ighly selected subsets of patients, and questions frequently
rise about the applicability of this RCT evidence to
real-world” patients, many of whom would not have been
ligible for enrollment due to age, co-existing illnesses, or
oncomitant medication use (15). Moreover, interventions
hat are complex or very costly are less likely to be adopted
n practice even if the supporting evidence is strong. Finally,
t has been repeatedly shown that the format of data
resentation also influences physician interpretation, with
reater enthusiasm engendered by RCTs reporting relative
reatment effects rather than absolute effects (16).
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
HF  heart failure
HOPE  Heart Outcomes Prevention and Evaluation
study
MI  myocardial infarction
RCT  randomized clinical trial
able 1. Barriers to the Application of Evidence in Clinical
are*
Barrier Examples
he Evidence Evidence of uncertain clinical significance
Evidence inconsistent between trials
Limited scope of the evidence
Lack of evidence in clinically relevant subgroups
Intervention complex or costly
Evidence inappropriately framed
Competing promotional influences
he Clinician Lack of motivation/clinical inertia
Lack of awareness or knowledge of the evidence
Disagreement with the intervention
Lack of self-efficacy†
Overemphasis on potential side effects
Competing promotional influences
he Patient Patient preferences/expectations/knowledge
Patient adherence
Competing promotional influences
he Setting Access to health care
Affordability (for the individual and the system)
Emphasis on acute symptoms rather than prevention
in most ambulatory care settings
Lack of time or resources
Lack of incentives to change
Lack of opinion leaders
Competing promotional influences
Based on references 3, 11, 25, and 38. †The belief that one cannot adequately
rerform a given recommendation.Second, clinicians must be motivated to alter their prac-
ice in light of new evidence. Although clinician age,
ender, and year of graduation appear to be associated with
ractice variation in some, but not all, studies, it is recog-
ized that prescribing patterns (and sometimes clinical
utcomes) do vary by physician specialty, even after adjust-
ng for differences in case mix (17). Of note, although there
s a relatively rich database documenting differences between
pecialties in the management of hospitalized patients with
cute myocardial infarction (MI) or HF (17–19), the evi-
ence base is less robust for differences in outpatient care
nd is an area of active research (20,21). Although being
ware of new evidence is a prerequisite to changing practice,
tudies examining physician knowledge while simulta-
eously measuring clinical practice have found remarkably
onsistent gaps between what we know and what we do,
ith a median absolute difference of 28% (22). Further,
lthough both specialists and generalists tend to over-
stimate the baseline risks of their patients (23,24), and at
east two surveys have demonstrated that both groups
stimated similar relative benefits for specified therapies,
on-specialists tended to substantially over-estimate poten-
ial side-effects (25,26). As a further example, while over
0% of European primary care physicians were aware of the
urvival benefits of beta-blockers in HF, two-thirds ex-
ressed reluctance to prescribe these agents without special-
st input, and only 21% of beta-blocker prescriptions were
nitiated by the primary care physician (6). The reluctance of
rimary care physicians to apply new evidence (“therapeutic
onservatism”) may be partially attributable to the fact that
atients seen in primary care are often older and have more
nrelated co-existing illnesses than the patients seen by
pecialists or the subjects entering RCTs (19).
Third, although patient preferences and expectations are
mportant to elicit for chronic therapies and should not be
iewed as a barrier to the provision of quality health care, it
ust be acknowledged that patients do not always agree
ith their physicians as to which therapies may be indicated
or their conditions and may decline proven efficacious
herapies even when presented with all of the evidence
27–29). On the other hand, well-informed and activated
atients may influence their clinicians to prescribe therapy
hen they may not have otherwise done so (29). Thus,
atient factors may represent a two-edged sword in at-
empting to translate evidence into clinical care. This is an
rea in need of further research. Finally, although it is
eyond the scope of this manuscript, patient adherence to
hronic preventive therapies is often suboptimal, and there
s a burgeoning evidence base on strategies to improve
edication adherence (30).
The hurried and harried nature of current medical care
ystems are well known to the reader. Although traditionally
t had been thought that the system barriers to best practice
argely resulted from lack of access to health care, recent
tudies have shown that even when patients are seen
egularly for chronic conditions such as hypertension, their
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Knowledge Translation in Cardiology May 19, 2004:1738–42reatment may be suboptimal (31,32). Thus, access to health
are is not in and of itself enough to ensure the closure of a
are gap. Lack of health care provider time, in fact, may be
he greater barrier. For example, in a recent simulation, it
as shown that primary care providers would need to spend
.4 h per day to provide all the preventive services recom-
ended by the U.S. Preventive Services Task Force before
hey could even start on their patients’ acute or chronic
roblems (33). In the current health care environment,
tructured and adequately resourced models of care, such as
isease management programs for HF (34), hold substantial
romise for the closure of care gaps and achievement of
etter disease-specific outcomes than individual clinicians.
Finally, the reader will note that we have mentioned
ompeting promotional influences under all four barrier
ategories in Table 1. Although this includes the obvious
harmaceutical industry promotional activities (for exam-
le, advertisements directed to providers or direct to
onsumers, detailing visits, or provision of free samples), it
hould be recognized that organizations or trial investigators
lso engage in promotional activities, and, when both types
f promotion work in concert, the effects may be substantial.
or example, we have recently demonstrated that, after the
ublication of the Heart Outcomes Prevention and Evalu-
tion (HOPE) trial, ramipril prescriptions increased by a
uch greater rate in Canada (where HOPE and ramipril
ere more actively promoted by the pharmaceutical industry
nd study investigators) than the U.S. (approximately 12%
s. 5% increase per month) (35,36). Needless to say,
romotional activities are not always a negative factor and,
n many cases such as with ACE inhibitor prescribing
ost-HOPE, serve to benefit individual patients and the
ealth care system.
HAT CAN BE DONE TO CLOSE CARE GAPS?
he well-described (22) gaps between knowledge and prac-
ice would imply that methods that rely solely on increasing
hysician knowledge through the passive transfer of unso-
icited, generic, and/or didactic information are unlikely to
ave a substantial impact on practice. This is, in fact, the
ase (3,37–39). Passive knowledge transfer strategies, such
s attending traditional continuing medical education lec-
ures or creating and disseminating clinical practice guide-
ines, have almost uniformly been demonstrated to have
ittle or no effect on clinical practice (3,37,38).
What must be understood is that lack of knowledge is but
ne barrier to the adoption of best evidence, and it may not
e as important as many of the other barriers outlined earlier
n Table 1. For example, in the management of MI,
ardiologists have greater knowledge of current evidence
han do generalists (40); however, when their actual prac-
ices are compared, and differences in case-mix accounted
or, it becomes apparent that this greater knowledge trans-
ates into very small differences in clinical practice (19,41).
ndeed, specialists may simply have a tendency to adopt new mractices more quickly—whether or not justified by the
vailable evidence (19). Again, if lack of knowledge is not
he primary determinant of the care gaps in cardiovascular
edicine, it is unlikely that simply increasing access to the
vidence or training housestaff or busy community-based
hysicians in the precepts of critical appraisal will lead to
mprovements in quality of care.
That is not to say that physician practice cannot be
hanged. Indeed, active and multifaceted knowledge imple-
entation strategies do consistently change practice, al-
hough the effects are often modest (Table 2) (3,37). For
xample, computerized real-time reminders in the office or
n the ward and practice audits with feedback that include
omparisons to local peers can modify practice (3,37). The
ormer have more to do with convenience and a “secretarial”
unction than increasing knowledge per se; the latter tend to
ork because realistic goals that can be achieved by one’s
ocal peers are presented as a benchmark rather than the
nattainable goal of “100% adherence” to guidelines (3,42).
f interest, the most consistently effective methods to
hange physician practice appear to be short face-to-face
ducational visits (“academic detailing”) and the use of
pinion leaders (3,37). Why? Perhaps because these two
able 2. Examples of Ineffective, Effective, and Potentially
ffective Knowledge Transfer Strategies*
neffective (or Minimally Effective) Strategies
Traditional didactic continuing medical education lectures (38)
Dissemination of newsletters
Dissemination of clinical practice guidelines (46)
Computerized guidelines (45)
Training in critical appraisal
Medication profiles
Drug utilization review, retrospective or prospective (39)
ffective Strategies
Audit and feedback with comparison to local peers (42)
Real-time clinical reminders, computerized or paper-based (47,48)
Face-to-face educational outreach (academic detailing)
Local opinion leaders (43)
Disease management approaches (34)
Computerized physician order entry (48)
Critical pathways
Multifaceted interventions, i.e., two or more strategies
otentially Effective Strategies That Need to be Better Studied
Use of lay media to influence patients and physicians
Generic samples and other forms of countermarketing
Patient decision aids and other forms of patient “activation” (49)
Continuous quality improvement strategies
Computerized decision support and other “E-health” strategies
(47,48)
Incentives, financial or otherwise, to promote best practice
Disincentives, financial or otherwise, to restrict suboptimal practice
Expanded roles and responsibilities for nonphysician providers (e.g.,
nurse practitioners, community-based pharmacists) (50)
Based primarily on references 3 and 37, which are systematic reviews of studies
ddressing each of the individual strategies. Some strategies that were not reviewed in
etail in references 3 and 37 have been referenced individually in the Table.ethods rely on using sociologically influential people (i.e.,
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May 19, 2004:1738–42 Knowledge Translation in Cardiologycademic detailers involved in quality improvement studies
end to be independent pharmacists who meet in person
ith physicians and provide unbiased advice, while opinion
eaders are educationally influential local specialists whose
ractice is emulated by their peers) to actively transmit
imple messages that convince physicians that it may be
orthwhile to apply the knowledge that they already have.
or example, one cluster-randomized controlled trial that
ested the influence of locally nominated opinion leaders on
mproving management of patients with MI demonstrated
mprovements in the use of aspirin and beta-blockers (43).
t is surely not a coincidence that detailing physicians and
nfluencing local opinion leaders are two methods routinely
sed by the pharmaceutical industry to change physician
ractice—to the tune of one billion dollars per month in the
.S. alone (35).
We need to accept that changing physician practice has less
o do with detailed knowledge of the evidence and more to do
ith being convinced that a particular patient may benefit by
pplying the evidence when the opportunity arises in our
linics. If so, the medical community needs to find more
onvincing ways to promote good evidence. Because primary
are physicians rely on the opinion of peers or local opinion
eaders over all other information sources (44), perhaps this
ctivity can be facilitated by creating a cadre of respected local
pecialists with the time and resources to appraise the evidence
n their discipline on an ongoing basis and then actively
romote it in their communities. Of course, this is a testable
ypothesis that should be subjected to a controlled trial.
In Table 2, we present some other potentially effective
nterventions that are either currently being tested or ought
o be tested in controlled studies of knowledge transfer
34,38,39,42,43,45–50). Of note, the physician practice
hange literature is strewn with many other good ideas that
eemed promising at first but when studied rigorously were
ound wanting (3,37). For instance, a cluster-randomized
rial recently demonstrated that computerized guidelines for
econdary prevention of coronary artery disease were no
etter than usual care when introduced into busy physicians’
ffices (45). Thus, we believe there is a need to rigorously
est those interventions that show promise before promoting
heir widespread adoption.
ONCLUSIONS
n summary, the translation of research evidence into
linical practice is unpredictable, inconsistent, and complex.
aps between best practice and usual practice are not solely
ue to knowledge deficits and, by extension, efforts to
nhance the application of evidence need to focus on
ultifaceted implementation schemes that recognize this.
hus, publication of a study in a journal should be seen as
he beginning of the journey to best practice, not the end. It
s heartening to see that funding agencies are recognizing
he need for more attention to, and more resources for,esearch into knowledge transfer. The road ahead is long
nd winding, and much remains to be defined in this field.
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